AbbVie stays bullish on future performance as Skyrizi continues to impress — but 'price controls' would be a game changer

John Carroll

Editor & Founder

AbbVie’s executive team stayed right on track in Q2, with its Skyrizi franchise — now newly approved for Crohn’s — continuing to rack up impressive sales …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie stays bullish on future performance as Skyrizi continues to impress — but 'price controls' would be a game changer

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Ionis’ treatment for a rare metabolic disorder

Sofinnova outlines $550M fund after IPOs and M&A deals

Ab­b­Vie stays bull­ish on fu­ture per­for­mance as Skyrizi con­tin­ues to im­press — but 'price con­trol­s' would be a game chang­er

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

AbbVie stays bullish on future performance as Skyrizi continues to impress — but 'price controls' would be a game changer

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Ionis’ treatment for a rare metabolic disorder

Sofinnova outlines $550M fund after IPOs and M&A deals